Related references
Note: Only part of the references are listed.Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study
Ignacio Conget et al.
DIABETES THERAPY (2021)
Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units . mL(-1) and Insulin Degludec 100 units . mL(-1) in Type 1 Diabetes
Paola Lucidi et al.
DIABETES CARE (2021)
Diabetes Advocacy: Standards of Medical Care in Diabetes-2019
DIABETES CARE (2020)
Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study
Maria S. Ruiz de Adana et al.
DIABETES CARE (2020)
Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
Athena Philis-Tsimikas et al.
DIABETOLOGIA (2020)
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Tadej Battelino et al.
DIABETES THERAPY (2020)
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross-over study using continuous glucose monitoring profiles
Yuji Kawaguchi et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study
Mizuho Yamabe et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation
D. R. Owens et al.
DIABETES & METABOLISM (2019)
Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes
T. S. Bailey et al.
DIABETES & METABOLISM (2018)
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
Julio Rosenstock et al.
DIABETES CARE (2018)
Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension)
Y. Terauchi et al.
DIABETES & METABOLISM (2017)
Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin-naive people with type 2 diabetes: 12-month results from the EDITION 3 trial
G. B. Bolli et al.
DIABETES & METABOLISM (2017)
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
Tim Heise et al.
DIABETES OBESITY & METABOLISM (2017)
New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)
M. Matsuhisa et al.
DIABETES OBESITY & METABOLISM (2016)
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
Philip D. Home et al.
DIABETES CARE (2015)
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
Tim Heise et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Psychometric analysis of the Spanish and Catalan versions of a questionnaire for hypoglycemia awareness
Marga Jansa et al.
MEDICINA CLINICA (2015)
New Insulin Glargine 300 Units.mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units.mL-1
Reinhard H. A. Becker et al.
DIABETES CARE (2015)
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Matthew C. Riddle et al.
DIABETES CARE (2014)
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
Hannele Yki-Jarvinen et al.
DIABETES CARE (2014)
The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
Luigi Meneghini et al.
DIABETES CARE (2013)
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial
B. W. Bode et al.
DIABETIC MEDICINE (2013)
Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes ( BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
Chantal Mathieu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial
Yukiko Onishi et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
Bernard Zinman et al.
DIABETES CARE (2012)
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Alan J. Garber et al.
LANCET (2012)
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Simon Heller et al.
LANCET (2012)
Share Paper
